Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 789-794

  Walsh, Fiona ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

MBC; MIC; Mutant; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFTAZIDIME; CILASTATIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; OXACILLIN; PENICILLIN G;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG UPTAKE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 36448940901     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Andes DR, Kiem S, Craig WA. 2003. In vivo pharmacodynamic activity of a new carbapenem, doripenem, against multiple bacteria in a routine thigh infection model Abstract A-308. In Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington DO American Society for Microbiology.
2. Bhavnani SM, Hammel JP, Cirincioni BB, et al. 2003. PK-PD target attainment with Monte Carlo simulation as decision support of Phase 2/3 dosing strategies for clinical development of doripenem Abstract A-11. In Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington DC: American Society for Microbiology.
3. Bhavnani SM, Hammel JP, Cirincione BB, et al. 2005. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother, 49:3944-7.
4. Bosso JA. 2005. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy, 25:55S-62S.
5. Fritsche TR, Stilwell MG, Jones RN. 2005. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect, 11:974-84.
6. Ge Y, Wikler MA, Sahm DF, et al. 2004. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother, 48:1384-86.
7. Jones RN, Huynh HK, Biedenbach DJ et al. 2004a. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother, 54:144-54.
8. Jones RN, Huynh HK, Biedenbach DJ. 2004b. Activities of doripenem (S4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother, 48:3136-40.
9. Mikamo H, Izumi K, Hua YX. 2000. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J Antimicrob Chemother, 46:471-4.
10. Mori M, Hikida M, Nishihara T, et al. 1996. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-1. J Antimicrob Chemother, 37:1034-6.
11. Musthaq S, Ge Y, Livermore DM. 2004a. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother, 48:1313-9.
12. Musthaq S, Ge Y, Livermore DM. 2004b. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother, 48:3086-92.
13. Thye DA, Kilfoil T, Leighton A. 2003. A phase I study evaluate safety, tolerability and pharmacokinetics in a Western healt volunteer population Abstract A21. In Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington DC: American Society for Microbiology.
14. Traczewski MM, Brown SD. 2006. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother, 50:819-21.
15. Tsuji M, Ishii Y, Ohno A. 1998. In vitro and in vivo antibacterial activities of S4661, a new carbapenem. Antimicrob Agents Chemother, 42:94-9.